Terra Tech Corp (OTCMKTS:TRTC) Strengthens Operations

Terra Tech Corp (OTCMKTS:TRTC)

Terra Tech Corp (OTCMKTS:TRTC) has signed a non-binding letter of intent paving way for it to complete the acquisition of a 50% stake in NuLeaf Sparks Cultivation LLC and NuLeaf Reno Production LLC. The acquisition should strengthen the company’s cannabis cultivation and production portfolio allowing it to introduce new wholesale cannabis brands in the market.

Terra Tech Corp (OTCMKTS:TRTC)
One month TRTC Stock Price Chart

Investors Reaction

Investors reacted to the acquisition push, sending the stock up 10.19%. TRTC stock is currently trading in a tight $0.22 to $0.26 trading range, waiting to see if the bullish momentum is strong enough to push it to 52-week highs of $0.56 a share. Terra Tech faces resistance at the $0.26 mark.

Terra Tech Corp (OTCMKTS:TRTC) is a cannabis focused Agriculture Company that operates through Hydroponic produce and Cannabis products. The company designs, develops, and markets hydroponic equipment in addition to hydroponic produce and floral products.

NuLeaf Acquisition

The acquisition of NuLeaf Sparks should strengthen the company’s cultivation business given that the company owns a medical cannabis cultivation license. The firm is also in the process of constructing a 30,000 square foot cannabis cultivation facility in Nevada.

NuLeaf Reno holdings, on the other hand, should strengthen the company’s production business as it holds a cannabis production license and is in the process of constructing 15000 square foot facility. Terra Tech Corp (OTCMKTS:TRTC) CEO, Derek Peterson believes the merger will help the company become a dominant force in Nevada legal cannabis business.

“This partnership will allow us to rapidly increase our time to market without needing to invest vast amounts of time or CapEx into establishing cultivation and production capabilities from scratch,” said Mr. Peterson.

The executive remains confident of the transaction closing in the third quarter thus allowing Terra Tech Corp (OTCMKTS:TRTC) to start generating revenues from joint operations before the end of the year. The new cultivation and production facilities will supply three of the company’s dispensaries in addition to third-party dispensaries in the state.

Separately, Terra Tech Corp (OTCMKTS:TRTC) subsidiary Edible Green has expanded its product line with the introduction of a new line of fresh cut herbs dubbed ‘Snip Its’. The new line of product is to go on sale in major retail outlets that support health and wellness.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TRTC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

PotNetwork Holdings Inc (OTCMKTS:POTN) Robust Sales Growth

PotNetwork Holdings Inc (OTCMKTS:POTN)

Shares of PotNetwork Holdings Inc (OTCMKTS:POTN) continues to elicit renewed investor interest as the company’s subsidiary Diamond CBD continues to gain traction in the lucrative legal cannabis business. The unit continues to exceed expectations having achieved record breaking revenues of $1.5 million in June.

PotNetwork Holdings Inc (OTCMKTS:POTN) has been trading in an upward trend for the better part of the year. The stock is currently trading at the high end of a $0.07-$0.08 trading range as it closes in on its 52-week high of $0.10 a share. It faces resistance at the $$0.08 mark.

PotNetwork Holdings Inc (OTCMKTS:POTN)
One month POTN stock price chart

Sales Growth

Increased sales expectations in the company’s cannabis unit should continue to fuel interest from investors looking for opportunities in the cannabis business. As the legal cannabis business heats up PotNetwork Holdings Inc (OTCMKTS:POTN) is poised to see growth in demand for its products.

PotNetwork Holdings Inc (OTCMKTS:POTN) reported sales of $5 million for the first two-quarters of the year. Sales in the second quarter alone stood at $3.2 million representing a 1,495% year over year increase. Given the sales momentum, the company remains on track to exceed its full year sales forecast.

Net profit for the first six months of the year stood at $369,237 with a positive net cash flow of $395,009.

“We are consistently setting new sales records month after month and are excited to be able to report this type of continuing growth. We have taken our marketing efforts seriously. A commitment that is surely being revealed in the ongoing sales numbers,” stated Maria Gomez, Regional Vice President of Sales for Diamond CBD, Inc.

PotNetwork Holdings Inc (OTCMKTS:POTN) robust growth has already attracted interest from equity firms which have initiated coverage of the stock. SeeThruEquity analysts buoyed by the company’s sales growth momentum has initiated coverage with a share price target of $0.25 a share.

Board of Advisors Appointment

Separately, POTNETWORK HLDGS I COM USD0.0001 (POST REV SPLI (OTCMKTS:POTN) has moved to strengthen its board of advisors with the appointment of Mr. David Feldbaum. His appointment is part of an effort that seeks to strengthen the level of expertise that Diamond CBD will have exposure to, as it moves to come up with new formulations and product lines.

“We expect that his experience and wisdom will strengthen the Company’s position in the industry as we target product lines to enhance wellness in his areas of expertise,” states Maria Gomez, Regional Vice President of Sales for Diamond CBD.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $POTN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

CANNA CONSUMER GOO COM NPV (OTCMKTS:CBMJ)

CANNA CONSUMER GOO COM NPV (OTCMKTS:CBMJ)’s $500,000 Financing Rattles Investors

CANNA CONSUMER GOO COM NPV (OTCMKTS:CBMJ)

CANNA CONSUMER GOO COM NPV (OTCMKTS:CBMJ) shed 30% in market value after announcing it had secured a new $500,000 funding commitment, from MGH. The company plans to use the amount to increase its buying power of mainstream media as it moves to pursue new clients and expand its reach in the multibillion cannabis industry.

CANNA CONSUMER GOO COM NPV (OTCMKTS:CBMJ)
One month CBMJ stock price chart

Stock Performance

The new funding appears to have spooked investors as it increases the company’s debt holdings. Wednesday’s sell-off brought an end to the bullish run that began early in the month. The stock is currently trading in a $0.02-$0.03 trading range. It awaits to be seen if the stock will continue to edge lower or if the selloff is a minor pull back.

Canna Broadcast Media/ Loudmouth is an established mainstream media placement company with relationships in Radio, Print, TV and online media. The company produces cannabis-based content that air in over 700 radio stations globally.

Growing Client List

Under the terms of the agreement, MFG is to transfer the $500,000 financing in pre-paid media placement opportunities and services. The cannabis broadcasting company can use the media assignment on television, radio, and digital display to market products for its clients.

“By receiving $500,000 in media funding, CANNA CONSUMER GOO COM NPV(OTCMKTS:CBMJ) is now able to increase its buying power of mainstream media for the cannabis industry which is expected to increase our margins, expand our reach, and allow us to place media for a greater number of clients,” said CEO, Mark Schaftlein.

The chief executive officer expects the funding to put the company in a stronger financial position as it pursues high net worth clients in the cannabis business. Canna funding solutions is one of the companies that has already bought media placement in CBMJ DBA worth $100,000. The placements are to be used to promote companies that the firm plans to invest in at the upcoming MJAC217 Investorhub International cannabis conference

CANNA CONSUMER GOO COM NPV (OTCMKTS:CBMJ) has already partnered Investorhub to bring mainstream awareness to the upcoming Los Angeles Premium Investment cannabis event. The company was selected as the official partner as it is the only media company in the cannabis space with access to mainstream network media.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CBMJ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Contracts Push Fuel Tech Inc (NASDAQ:FTEK) Higher

Fuel Tech Inc (NASDAQ:FTEK)

Fuel Tech Inc (NASDAQ:FTEK) rallied 12.59% after announcing receipts for multiple air pollution control contracts from customers in the U.S., China, and Europe. The contracts are poised to inject approximately $6.9 million into the company’s balance sheet once implemented.

Fuel Tech Inc (NASDAQ:FTEK)
One month FTEK stock price chart

Stock Performance

Fuel Tech Inc (NASDAQ:FTEK) gapped higher on the new contract orders, touching highs of $1.20 a share in the process, before retreating to close at $0.94 a share. The rally marked the stock’s biggest run, having been under immense selling pressure for the better part of the year.

The stock is currently trading in a $0.85-$1.19 trading range at the back of renewed investor interest in the wake of the new contracts. A close above the $0.95 mark could see the stock rally to the $1.20 mark where it faces resistance.

Fuel Tech Inc (NASDAQ:FTEK) is a technology company focused on the development and commercialization of technologies for air pollution, control, and process optimization. The company operates through three segments of Air Pollution control technology, Fuel Chem technology, and Fuel conversion.

Air Pollution Control Contracts

The new contract orders include three orders for the company’s Ultra systems that are to be installed in coal and solid waste fired units in China. Delivery of the systems should begin in the third quarter. The other two orders are for the company’s NOxOUT® Selective Non-Catalytic Reduction (SNCR) systems of which deliveries are poised to begin in the first quarter of 2018.

Fuel Tech has also received an order for its Fuel Tech Inc (NASDAQ:FTEK)’s NOxOUT® SNCR technology to be installed at the U. S. facility. In Europe, the company will upgrade existing SNCR systems with deliveries set to be complete by the end of the fourth quarter.

“These orders reflect Fuel Tech’s ability to provide safe, cost-effective environmental and emission control solutions for units utilizing a variety of fuel sources, including natural gas and solid waste,” said Vincent J. Arnone, President and Chief Executive Officer of Fuel Tech.

The new Air Pollution contract orders add to Fuel Tech Inc (NASDAQ:FTEK) backlog that stood at $21.4 million at the end of June. The Company has so far received orders worth $29 million for the year. The Chief Executive Officer expects significant improvement in the company’s operating performance in the second half of the year, driven by reduced operating costs and backlog to revenue conversion.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $FTEK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc (NASDAQ:OTIC) Stock Slammed

Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc (NASDAQ:OTIC) stock felt the market’s wrath after its novel treatment for Meniere’s disease, OTIVIDEX, failed to meet its primary endpoint in a Phase 3 clinical trial. Investors sent the stock tumbling 82.81% to lows of $3.45 following the disappointing clinical trial results.

Otonomy Inc (NASDAQ:OTIC)
One month OTIC stock price chart.

Lost Opportunity

The biopharmaceutical company shed more than80% of its market value after confirming it was suspending development of OTIVIDEX for chronic disorder of the inner ear. The stock registered a new 52-week low of $3.45 and is currently trading in a $3.45-$4.20 trading range.

Prior to the selloff, Otonomy Inc. (NASDAQ:OTIC) stock was trading over $20 a share as investors remained confident about OTIVIDEX prospects. The U.S. Food and Drug Administration (FDA) is yet to approve any drug for Meniere’s disease. Patients struggling with the chronic medical condition have to contend with compounded steroids to combat the effects of the disease.

Successful clinical trials could have exposed Otonomy Inc (NASDAQ:OTIC) stock to a $500 million market opportunity in the U.S. alone, according to Cowen & Co analyst Ken Cacciatore. The technology behind OTIVIDEX is currently in use in another ear infection drug that generated $300,000 in revenue for the company in the second quarter.

OTIVIDEX Phase 3 Trial Results

According to the biopharmaceutical company, OTIVIDEX therapy showed similar reductions in the number and severity of vertigo episodes compared to Placebo. The candidate drug missed its primary endpoint which was the count of definitive vertigo days. It also failed to meet its secondary goals.

“Based on these results, we are immediately suspending all development activities for OTIVIDEX including the ongoing AVERTS-2 trial. In addition, the company is undertaking a review of its product pipeline and commercial efforts to identify opportunities to extend its cash runway and build shareholder value,” said CEO, David Weber.

Guidance Suspension

In the wake of the disappointing clinical trial results, Otonomy Inc (NASDAQ:OTIC) has withdrawn its spending guidance for the year as it moves to review its business. The company had a total of $150.5 million in cash and cash equivalent as of the end of the second quarter of which it planned to use between $80-85 million as operating expense.

The disappointing clinical trial results and the stock sell off wave has since evoked a wave of class action investigations from law firms. A number of law firms are currently investigating the company over possible violations of federal security laws.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OTIC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

One Horizon Group Inc (NASDAQ:OHGI) Commences $500,000 Contract

One Horizon Group Inc (NASDAQ:OHGI)

Shares of One Horizon Group Inc (NASDAQ:OHGI) bounced from all-time lows after the company announced it had started work on a contract that could generate as much as $500,000 in revenue for the second half of the year. Investors reacted to the news by sending the stock up almost 65% to close at $1.23 a share.

The massive rally pushed the stock to a key resistance level of $1.50 a share. The stock is currently trading in a downtrend, in a $0.75-$1.39 trading range. The rally further goes to strengthen One Horizon Group Inc (NASDAQ:OHGI)’s compliance with the NASDAQ minimum bid requirement.

One Horizon Group Inc (NASDAQ:OHGI)
One month OHGI Stock Chart

OHGI Stock Performance

One Horizon Group Inc. (NASDAQ:OHGI) is a leading provider of secure instant messaging software. The company provides real time communication to millions of people. Fuelling renewed investor interest in the stock is the company’s new contract with a Hong Kong based customer.

“As a result of this contract and expected future growth, combined with lower overheads and reduced cash outlays resulting from the recent disposition of VoIP subsidiaries, we expect the Company to be cash flow positive in the near term,” said Martin Ward, Principal Executive Officer.

The sizable contract requires the company to furnish the client with secure messaging software. The contract should go a long way in affirming the company’s push for growth. One Horizon Group Inc (NASDAQ:OHGI) has already set its eyes on China and Hong Kong’s gaming, security and education sectors in pursuit of new opportunities for growth.

Expansion Drive

During the first quarter, One Horizon Group Inc (NASDAQ:OHGI) secured a license that paves the way for it to expand its footprint in Ghana. The company is gearing up to provide the benefits of voice communications to over 18 million mobile data subscribers in the West African nation. The company is also in the process of pursuing opportunities in the mobile hot spot market having signed a licensing agreement with a leading pocket Wi-Fi service provider.

Separately, Horizon Group Inc (NASDAQ:OHGI) has repaid a debt of $662,048 owed to the Principal Officer through the issuance of 859,802 shares of common stock. In addition, the company generated a net loss of (-$1.28) million for the first three months of the year compared to a net loss of (-$1.26 million) for the corresponding period last year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OHGI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Tandem Diabetes Care Inc (NASDAQ:TNDM)

Stock Soaring for Tandem Diabetes Care Inc (NASDAQ:TNDM)

Tandem Diabetes Care Inc (NASDAQ:TNDM)

Tandem Diabetes Care Inc (NASDAQ:TNDM) stock is up over 50% in early trading on volume, that if continued, would be over 100 times their 30-day, daily average. The market is responding to news that the U.S. Food and Drug Administration (FDA) approved the commercial launch of the t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration. This technology is the first sensor-augmented insulin pump approved to let users make treatment decisions without the need for pricking one’s finger.

About Tandem Diabetes Care Inc.

San Diego, CA-based Tandem Diabetes Care Inc (NASDAQ:TNDM) is a medical device company. The company designs, develops, and commercializes medical deices for people with insulin-dependent diabetes. The company’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, along with a disposable insulin cartridge, and an infusion set. The company also offers its Tandem Device Updater. This web-based system lets users update their pump’s software and adjust the t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters.

TNDM Stock Performance

Tandem Diabetes Care Inc (NASDAQ:TNDM)
One month stock price chart for TNDM

Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) closed Friday at $0.70, then gapped up to open at $0.92 before hitting its inter-day high (a/o 10:45 AMEST) of $1.22. TNDM stock has performed poorly tear-to-date and lost over 67%. For the year they have dropped almost 90%. The company has not been kind to shareholders on the earnings side either. For 2016, the company had an EPS loss of (-$2.73) and has not posted a profit in the past four years. However, sales have been steadily improving. In 2012 the company posted sales of $2.5 million. That annual figure has improved every year and in 2016 the company reported $84.2 million in sales. The analyst’s consensus price target for TNDM stock is $2.88.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TNDM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Origin Agritech Ltd. (NASDAQ:SEED)

Origin Agritech Ltd. (NASDAQ:SEED) Receives Payment For Seed Business

Origin Agritech Ltd. (NASDAQ:SEED)

Shares of Origin Agritech Ltd. (NASDAQ:SEED) rallied 21.62% after the company announced it had received RMB 152 million as the first batch payment of RMB421 with regard to the sale of its corn seed production and distribution business to Beijing Shihui.  The selloff is part of a restructuring push that seeks to align the company’s operations to leading agricultural biotechnology and corn seed breeding programs.

Origin Agritech Ltd. (NASDAQ:SEED)
One month stock chart for SEED

Stock Performance

Shares of Origin Agritech Ltd. (NASDAQ:SEED) are currently trading in an upward trend after bouncing back from this year’s low of $1.40 a share. The stock is trading in a tight $1.51 to $1.96 trading range with immediate resistance at the $1.90 mark, above which it could rise to $2.20 mark.

Origin Agritech Ltd. (NASDAQ:SEED) is an agricultural biotechnology company specializing in the development, production, and distribution of hybrid seeds. The company also specializes in crop seed breeding, genetic improvement, and related technical services.

In April, Origin Agritech Ltd. (NASDAQ:SEED) sold its Corn, seed production and distribution business as it sought to reposition its commercial seed business for stronger future growth. Under the terms of an agreement, Beijing Shihui is to make an additional payment of RMB 69 Million, before November 15, 2017.

The buyer is also to make a final payment of RMB 200 million including an initial RMB 10 million down payment, no later than December 15, 2017. Origin Agritech Ltd. (NASDAQ:SEED) also retained its corn breeding and biotech research programs as well as all intellectual properties as part of the sell-off agreement.

Origin Agritech Big Play

The company’s chief executive officer, Bill Niebur, expects proceeds from the sale to spearhead the company’s journey to becoming a leading international corn seed technology company.

“The proceeds significantly accelerate and expand our capabilities to develop and deliver corn biotechnology traits and corn product licensing business within China and around the globe. All current indicators point to a near-term commercial launch for the projected USD 5-6 billion GM-trained corn seed market in China,” said Mr. Niebur.

Origin Agritech Ltd. (NASDAQ:SEED) already boasts of a leading corn, germplasm collection and biotech trait platform that it plans to use to address strong customer demand for superior products. The company is also eyeing strategic partnerships with leading agricultural multinationals and Chinese seed companies as it looks to pursue growth opportunities in China’s seed market.

Separately. Mr. Niebur recently purchased 73, 530 of the company’s treasury shares valued at $100,000. The private placement purchase occurred at a purchase price of $1.36 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SEED and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

CareDx Inc (NASDAQ:CDNA)

CareDx Inc (NASDAQ:CDNA) Explodes On Medicare Coverage Approval

CareDx Inc (NASDAQ:CDNA)

Shares of CareDx Inc (NASDAQ:CDNA) rallied 33.022% as investors reacted to the approval of the company’s transplant surveillance solution, AlloSure, for Medicare coverage. The Center for Medicare and Medicaid Services have already released the final version of the coverage policy that paves way for the solution to be made available in hospitals starting October.

CareDx Inc (NASDAQ:CDNA)
One month stock price chart for CDNA

Stock Performance

Medicare approval of AlloSure continues to fuel renewed investor interest on CareDx Inc (NASDAQ:CDNA), which has been under immense selling pressure for the better part of the year. However, Wednesday’s rally reaffirmed a bullish rally that began early in the month. The stock faces immediate resistance at the $3.07 mark above which it could rise to the $4 mark.

CareDx Inc (NASDAQ:CDNA) is a molecular diagnostic company focused on the development of solutions for monitoring transplant patients. Its lead product is the AlloMap heart transplant molecular test, designed to help clinicians monitor and identify heart transplant recipients. AlloSure, on the other hand, is a transplant surveillance solution that applies next generation sequencing to detect genetic differences between donors and recipients.

AlloSure Medicare Coverage

CareDx Inc. (NASDAQ:CDNA) has already hit the ground running in its bid to make AlloSure available on all transplant centers across the U.S, following the Medicare milestone. The company expects increased interest on AlloSure given that Medicare usually covers about 80% of kidney transplant patients.

“We are hearing great interest from transplant nephrologists who want to begin using AlloSure as soon as CMS approval is finalized. We see the coverage decision by the MolDX team as a great signal for the support of kidney transplant patients and an acknowledgment of the unmet medical need,” said Peter Maag, Chief Executive Officer.

Medicare coverage should go a long way in strengthening CareDx Inc (NASDAQ:CDNA) high-value diagnostic solutions portfolio that already boasts of AlloMap in use in heart transplant centers. AlloMap is slowly becoming a standard care for monitoring heart transplant patients for the probability of rejection.

Q2 Earning Report

Medicare approval marks yet another milestone in CareDx Inc. (NASDAQ:CDNA) growth trajectory that became clear with the posting of stellar second quarter earnings. During the quarter, the company generated revenues of $12 million up from $10.7 million reported in Q2 2016. Net loss in the quarter more than halved to $4 million compared to $10.5 million reported last year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CDNA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Leafbuyer Technologies Inc. (OTCMKTS:LBUY)

Leafbuyer Technologies Inc. (OTCMKTS:LBUY) Extends Partnership

Leafbuyer Technologies Inc. (OTCMKTS:LBUY)

Shares of Leafbuyer Technologies Inc. (OTCMKTS:LBUY) were up by 36.23% after the company renewed their partnership with the Denver Post’s Cannabist. Under the terms of the agreement, the company is to remain as the official deal partner for the marijuana news website.

Leafbuyer Technologies Inc. (OTCMKTS:LBUY) will continue to host a ‘Deals Widget’ on every page of the Cannabist website going forward. The widget is designed to assist consumers in searching for the best cannabis deals in their area without leaving the website.

Stock Performance

Leafbuyer Technologies Inc. (OTCMKTS:LBUY) continues to move higher on a bullish run that began in May. The stock is currently trading at the high end of its $2.70-3.65 trading range with traders awaiting to see if the momentum is strong enough for a rally to the 52-week high of $10.50 a share.

Leafbuyer Technologies Inc. (OTCMKTS:LBUY)
One month stock price chart for LBUY

The company operates an online platform for offering cannabis deals and specials. The platform also allows consumers to connect with dispensaries. Leafbuyer also signs deals designed to expand its market reach to customers.

Cannabist Partnership

The company’s chief executive officer Kurt Rossner expects the continued partnership with Cannabist to help the company reach more consumers. The renewed partnership comes on the heels of Leafbuyer Technologies Inc. (OTCMKTS:LBUY) announcing a sales expansion strategy as it seeks to target more customers in the West Coast’s legal cannabis market.

“We believe having the right partnerships with established industry heavyweights will help expand Leaf buyer’s brand nationally. We expect 2018 will be a watershed year in this industry and we are excited to grow with the Cannabist,” said Mr. Rossner.

Leafbuyer Technologies Inc. (OTCMKTS:LBUY) is banking on the Cannabist partnership to further strengthen its footprint in the burgeoning California legal cannabis business. In a bid to increase exposure to out of state consumers and tourists, the Cannabist platform is to be included in the premium subscription for Leafbuyer consumers

Leafbuyer Technologies Inc. (OTCMKTS:LBUY) has already set its eyes on the California recreational marijuana market that is set to open next year. Expansion of the market place is poised to come into play which should allow the company to target customers above the age of 21 years in addition to medical marijuana customers.

Being a fast mover in the California and Colorado recreational marijuana market is important as legal cannabis businesses are poised to explode over the next five years. Gaining a competitive edge will thus be key if Leafbuyer Technologies Inc. (OTCMKTS:LBUY) is to accrue a substantial amount of market share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LBUY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.